Diplomat Pharmacy, Inc. (DPLO) Shares Bought by Invictus RG

Invictus RG raised its stake in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 24.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,820 shares of the company’s stock after acquiring an additional 2,707 shares during the quarter. Invictus RG’s holdings in Diplomat Pharmacy were worth $286,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. State of Alaska Department of Revenue increased its holdings in shares of Diplomat Pharmacy by 80.0% in the 2nd quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock worth $127,000 after acquiring an additional 3,833 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Diplomat Pharmacy by 46.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after acquiring an additional 2,794 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Diplomat Pharmacy in the 3rd quarter worth about $191,000. Municipal Employees Retirement System of Michigan increased its holdings in shares of Diplomat Pharmacy by 4.9% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after acquiring an additional 480 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in shares of Diplomat Pharmacy by 11.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 11,193 shares of the company’s stock worth $166,000 after acquiring an additional 1,193 shares during the period. Hedge funds and other institutional investors own 72.48% of the company’s stock.

Diplomat Pharmacy, Inc. (NYSE DPLO) opened at $18.28 on Thursday. The stock has a market cap of $1,254.87, a P/E ratio of 23.66, a PEG ratio of 3.29 and a beta of 0.61. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18. Diplomat Pharmacy, Inc. has a 52 week low of $12.25 and a 52 week high of $21.99.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.10. The company had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The business’s revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS. research analysts expect that Diplomat Pharmacy, Inc. will post 0.85 earnings per share for the current fiscal year.

A number of analysts recently weighed in on DPLO shares. Robert W. Baird cut shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $24.00 to $18.00 in a report on Thursday, November 16th. BidaskClub cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Mizuho raised their target price on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, November 7th. Leerink Swann raised their target price on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “market perform” rating in a research note on Tuesday, November 7th. Finally, Zacks Investment Research raised shares of Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, October 10th. Six investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $20.39.

In other news, Director Jeffrey G. Park bought 3,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was bought at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the completion of the acquisition, the director now directly owns 7,640 shares in the company, valued at approximately $118,114.40. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Atul Kavthekar purchased 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average price of $15.00 per share, with a total value of $30,000.00. Following the completion of the acquisition, the chief financial officer now owns 2,000 shares of the company’s stock, valued at approximately $30,000. The disclosure for this purchase can be found here. Insiders bought a total of 15,000 shares of company stock worth $228,780 in the last ninety days. Corporate insiders own 30.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.com-unik.info/2017/12/07/diplomat-pharmacy-inc-dplo-shares-bought-by-invictus-rg.html.

Diplomat Pharmacy Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

What are top analysts saying about Diplomat Pharmacy Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Diplomat Pharmacy Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit